← All trials
NCT07115238
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 20, 2024
- Primary completion
- Dec 31, 2025
- Completion date
- Jun 30, 2026
- First posted
- Aug 11, 2025
- Last posted
- Aug 11, 2025
- Enrollment
- 354
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sinotau Pharmaceutical GroupLead sponsor
- University of Science and Technology of ChinaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.